· Published by Health Canada · Official notice
This is duplicated text of a letter from Paladin Labs Inc.
Contact the company for a copy of any references, attachments or enclosures.
November 25, 2010
Subject: Recall and Withdrawal of NDarvon-N® (dextropropoxyphene) in Canada
Dear Health Care Professional,
In collaboration with Health Canada, Paladin Labs Inc. has decided to voluntarily recall and withdraw all lots of NDarvon-N® (dextropropoxyphene, also known as propoxyphene) on the Canadian market and discontinue the sale of the product. This decision follows a United States Food and Drug Administration (FDA) request that all manufacturers of propoxyphene, an opioid pain reliever used to treat mild to moderate pain, withdraw their products from the U.S. market The withdrawal is based on all available data, including data from a new study that evaluated the effects of increasing doses of dextropropoxyphene on the heart. Footnote 1
Additionally, Healthcare Professionals should:
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious heart rhythm abnormalities or other serious or unexpected adverse reactions in patients receiving NDarvon-N® should be reported to Paladin Labs Inc. or Health Canada.
Paladin Labs Inc.
6111 Royalmount Ave., Suite 102, Montreal, Quebec H4P 2T4
Telephone: 1-888-550-6060
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
To change your mailing address or fax number, contact the Market Authorization Holder (Industry).
Paladin Labs Inc. is committed to supplying you with high quality products and ensuring the highest level of patient care. Please do not hesitate to contact our Medical Services at 1-888-550-6060 if you need any additional information concerning this product recall and withdrawal.
Sincerely yours,
original signed by
Patrice Larose, B.Pharm., Ph.D.
Vice-President, Scientific Affairs
Link to study information on Food and Drug Administration Website. (PDF Version - 2,10K)